Scarica l'app Stockscreener
32.17
2.69%
-0.89
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Alliancebernstein L.P. Sells 75,151 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Polar Asset Management Partners Inc. Invests $378,000 in Vaxcyte, Inc. $PCVX - MarketBeat
FMR LLC's Strategic Acquisition of Vaxcyte Inc Shares - GuruFocus
Vaxcyte (PCVX) Initiates Coverage with Neutral Rating by Goldman Sachs | PCVX Stock News - GuruFocus
Goldman Sachs initiates Vaxcyte stock coverage with Neutral rating By Investing.com - Investing.com Canada
TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling - uk.finance.yahoo.com
Vaxcyte, Inc. $PCVX Shares Sold by Woodline Partners LP - MarketBeat
Fred Alger Management LLC Cuts Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Jones Financial Companies Lllp Has $6.27 Million Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Amundi Sells 63,416 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Stock Price, Quotes and Forecasts | NASDAQ:PCVX - Benzinga
Alyeska Investment Group L.P. Sells 32,945 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Can Vaxcyte Inc. continue delivering strong returnsJuly 2025 Price Swings & Accurate Entry/Exit Alerts - Lancaster City Council
Cormorant Asset Management LP Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
What is Vaxcyte Inc. s 5 year growth outlook2025 Trading Recap & AI Driven Stock Reports - beatles.ru
Is Vaxcyte Inc.’s growth already priced inWeekly Stock Report & Fast Exit and Entry Trade Guides - beatles.ru
Allostery Investments LP Takes $1.21 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
First Light Asset Management LLC Makes New Investment in Vaxcyte, Inc. $PCVX - MarketBeat
What indicators show strength in Vaxcyte Inc.Weekly Investment Summary & Growth Oriented Trade Recommendations - Newser
ADAR1 Capital Management LLC Makes New $483,000 Investment in Vaxcyte, Inc. $PCVX - MarketBeat
What are Vaxcyte Inc.’s growth leversRate Hike & Daily Profit Maximizing Tips - خودرو بانک
What are Vaxcyte Inc.’s recent SEC filings showingNew Guidance & Daily Chart Pattern Signal Reports - خودرو بانک
Vaxcyte, Inc. shares rise 3.73% intraday after presenting at Cantor Global Healthcare Conference. - AInvest
Vaxcyte Inc. stock outlook for YEARJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Short interest data insights for Vaxcyte Inc.2025 Momentum Check & Fast Moving Stock Watchlists - Newser
Vaxcyte Inc. stock trend forecastGold Moves & Free Safe Entry Trade Signal Reports - Newser
Is Vaxcyte Inc. forming a bottoming base2025 Key Highlights & Risk Controlled Stock Alerts - Newser
Will Vaxcyte Inc. stock recover after earningsQuarterly Portfolio Report & Long-Term Safe Investment Ideas - خودرو بانک
Advanced analytics toolkit walkthrough for Vaxcyte Inc.Earnings Miss & High Conviction Investment Ideas - Newser
Is Vaxcyte Inc. stock technically oversoldMarket Trend Review & Proven Capital Preservation Tips - خودرو بانک
Raymond James Financial Inc. Acquires 28,430 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
How to forecast Vaxcyte Inc. trends using time seriesJuly 2025 Summary & Daily Price Action Insights - Newser
Multi factor analysis applied to Vaxcyte Inc.2025 Earnings Impact & Weekly Market Pulse Updates - Newser
How to interpret RSI for Vaxcyte Inc. stockJuly 2025 Catalysts & Consistent Income Trade Recommendations - Newser
Live market analysis of Vaxcyte Inc.Weekly Profit Report & Safe Entry Point Identification - Newser
Is Vaxcyte Inc. forming a reversal patternJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - Newser
Vaxcyte advances VAX-31 pneumococcal vaccine to final stage of infant study - Investing.com Canada
Visualizing Vaxcyte Inc. stock with heatmapsEarnings Miss & Advanced Swing Trade Entry Alerts - Newser
Analyzing Vaxcyte Inc. with risk reward ratio charts2025 Support & Resistance & Safe Swing Trade Setups - Newser
Vaxcyte shares rise 1.90% after-hours as VAX-31 Phase 2 study advances to final stage. - AInvest
Vaxcyte Says VAX-31 Pneumococcal Disease Study Advances to Final Stage - MarketScreener
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose - The Manila Times
Vaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal Disease - Quiver Quantitative
92% Disease Coverage: Vaxcyte's VAX-31 Could Become Broadest Pneumococcal Vaccine for Infants - Stock Titan
What recovery options are there for Vaxcyte Inc.2025 Top Gainers & High Conviction Investment Ideas - Newser
How to build a custom watchlist for Vaxcyte Inc.July 2025 Update & Community Supported Trade Ideas - Newser
Evaluating Vaxcyte Inc. with trendline analysisWeekly Profit Summary & Long Hold Capital Preservation Tips - Newser
How institutional ownership impacts Vaxcyte Inc. stockMarket Sentiment Report & Verified Swing Trading Watchlist - Newser
What is the target price for Vaxcyte Inc. stock2025 Trading Volume Trends & Trade Opportunity Analysis Reports - khodrobank.com
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):